Management — Initial therapy / Multimodality therapy
• Novel agent with prior nonrefractory exposure and CNS penetration: IMiDs (pomalidomide, lenalidomide, thalidomide), venetoclax for t(11;14) ±
• Intrathecal methotrexate/cytarabine ± steroid
• Intrathecal thiotepa/steroid
• Radiation therapy
• Evaluation for BCMA CAR T-cell therapy if not previously received
• Palliative care consultation